Filing Flows › 8-K events › Prothena Corp Public
Prothena Corp Public: termination of a material definitive agreement
Form 8-K filed Oct 29, 2026 · items 1.02
What the filing says
Following an internal strategic review, Bristol Myers Squibb informed Prothena Corporation plc (the “ Company ”) on October 28, 2026 that it has decided not to advance PRX019 further in the clinic. In May 2024, a subsidiary of the Company entered into an exclusive global license agreement for PRX019 with Bristol Myers
Read the filing on SEC EDGAR →
What usually followsAcross 2,368 8-Ks reporting Item 1.02 (termination of a material agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.5%, up 51% of the time); over the following 21 sessions, +1.1%. Every item ranked →
What this kind of filing means
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
Prothena Corp Public at a glance
Prothena Corp Public, Q3 2026: revenue $620K (-74% year over year). The chart follows the revenue to costs, profit and cash.
Prothena Corp Public: every quarter, Q/Q and Y/Y, holders and guidance →
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.